Immix Biopharma, Inc. (IMMX )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol IMMX
- Company Immix Biopharma, Inc.
- Price $4.01
- Changes Percentage -4.75
- Change -0.2
- Day Low $4
- Day High $4.6
- Year High $4.6
- Year Low $1.34
- Market Cap $135,132,452
- Price Avg 50 EMA (D) $2.74
- Price Avg 200 EMA (D) $2.26
- Exchange NASDAQ
- Volume 1,230,833
- Average Volume 482,535
- Open $4.2
- Previous Close $4.21
- EPS -0.77
- PE -5.23
- Earnings Announcement 2026-03-23 04:00:00
- Shares Outstanding $33,573,280
Company brief: IMMIX BIOPHARMA, INC. (IMMX )
- Healthcare
- Biotechnology
- Dr. Ilya Rachman M.B.A., M.D., MBA, Ph.D.
- https://www.immixbio.com
- US
- N/A
- 12-16-2021
- US45258H1068
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.